

Barry A Siegel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/596523/publications.pdf>

Version: 2024-02-01

71
papers

5,495
citations

126907

33
h-index

98798

67
g-index

75
all docs

75
docs citations

75
times ranked

5622
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. <i>JAMA Network Open</i> , 2022, 5, e228392.	5.9	44
2	Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography. <i>Gynecologic Oncology</i> , 2022, , .	1.4	0
3	Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for 18F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometastatic disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 365.e9-365.e16.	1.6	12
4	Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. <i>Clinical Cancer Research</i> , 2021, 27, 3674-3682.	7.0	179
5	Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy. <i>Nature Communications</i> , 2021, 12, 733.	12.8	33
6	Using 18F-Fluciclovine PET/CT to Detect Prostate Cancer Recurrence in Patients With Very Low PSA Levels. <i>American Journal of Roentgenology</i> , 2021, 216, W10-W10.	2.2	1
7	39607 Mapping the Draining Lymph Nodes in Central Nervous System Malignancies. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 37-37.	0.6	0
8	Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4245-4255.	7.0	15
9	A Bayesian approach to tissue-fraction estimation for oncological PET segmentation. <i>Physics in Medicine and Biology</i> , 2021, 66, 124002.	3.0	14
10	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 61-61.	0.4	2
11	A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ¹⁸ F-DCFPyL in Prostate Cancer Patients (OSPREY). <i>Journal of Urology</i> , 2021, 206, 52-61.	0.4	180
12	Objective Task-Based Evaluation of Artificial Intelligence-Based Medical Imaging Methods. <i>PET Clinics</i> , 2021, 16, 493-511.	3.0	25
13	Radiologic Assessment of Groin Lymph Nodes in Pelvic Malignancies. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 947-953.	2.5	4
14	FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. <i>Gynecologic Oncology</i> , 2020, 157, 639-643.	1.4	57
15	Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1088-1097.	0.8	57
16	Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1286.	7.4	391
17	ICP12: PREDICTORS OF AMYLOID POSITIVITY IN COGNITIVELY IMPAIRED PATIENTS: DATA FROM THE IMAGING DEMENTIA EVIDENCE FOR AMYLOID SCANNING (IDEAS) STUDY. <i>Alzheimer's and Dementia</i> , 2019, 15, P21.	0.8	1
18	The Impact of Positron Emission Tomography with ¹⁸ F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. <i>Journal of Urology</i> , 2019, 201, 322-331.	0.4	113

#	ARTICLE	IF	CITATIONS
19	Evaluation of [⁸⁹ Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 523-530.	2.5	59
20	Hospice Admission and Survival After ¹⁸ F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2018, 59, 427-433.	5.0	13
21	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. <i>Blood</i> , 2018, 131, 182-190.	1.4	130
22	Intended Versus Inferred Treatment After ¹⁸ F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2018, 59, 421-426.	5.0	12
23	Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. <i>British Journal of Cancer</i> , 2018, 118, 72-78.	6.4	46
24	Safety and pharmacokinetics of MM-302, a HER2-targeted antibody- ⁶⁴ Cu-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. <i>British Journal of Cancer</i> , 2018, 119, 1086-1093.	6.4	75
25	Spatial relationship of 2-deoxy-2-[¹⁸ F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer. <i>EJNMMI Research</i> , 2018, 8, 52.	2.5	11
26	Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. <i>Lancet Oncology</i> , 2018, 19, 1082-1093.	10.7	21
27	Extensive Metastatic Sarcomatoid Renal Cell Carcinoma Evaluated by ¹⁸ F-FDG PET/CT: a Case Report and Review of Literature. <i>Journal of Kidney Cancer and VHL</i> , 2018, 5, 1-6.	1.0	7
28	Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. <i>Radiotherapy and Oncology</i> , 2017, 122, 445-451.	0.6	12
29	Performance Observations of Scanner Qualification of NCI-Designated Cancer Centers: Results From the Centers of Quantitative Imaging Excellence (CQIE) Program. <i>Academic Radiology</i> , 2017, 24, 232-245.	2.5	9
30	Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2017, 11, 338-345.	2.6	9
31	First-in-Man Evaluation of ¹²⁴ I-PGN650: A PET Tracer for Detecting Phosphatidylserine as a Biomarker of the Solid Tumor Microenvironment. <i>Molecular Imaging</i> , 2017, 16, 153601211773334.	1.4	12
32	Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1969-1983.	6.4	62
33	Reliability of PET/CT Shape and Heterogeneity Features in Functional and Morphologic Components of Non-Small Cell Lung Cancer Tumors: A Repeatability Analysis in a Prospective Multicenter Cohort. <i>Journal of Nuclear Medicine</i> , 2017, 58, 406-411.	5.0	131
34	Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 17-24.	6.4	98
35	Impact on Patient Management of [¹⁸ F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry. <i>Oncologist</i> , 2016, 21, 1079-1084.	3.7	11
36	Phase 1 Evaluation of [⁶⁴ Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. <i>Molecular Imaging and Biology</i> , 2016, 18, 446-453.	2.6	40

#	ARTICLE	IF	CITATIONS
37	PET/CT is a cost-effective tool against cancer: synergy supersedes singularity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1749-1752.	6.4	19
38	[⁸⁹ Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 952-959.	2.6	103
39	[¹²⁴ I]FIAU: Human dosimetry and infection imaging in patients with suspected prosthetic joint infection. <i>Nuclear Medicine and Biology</i> , 2016, 43, 273-279.	0.6	47
40	Pretreatment ¹⁸ F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235. <i>Journal of Nuclear Medicine</i> , 2016, 57, 842-848.	5.0	75
41	FTS-0402: Imaging dementia: Evidence for amyloid scanning (IDEAS) – a national study to evaluate the clinical utility of amyloid PET. <i>Alzheimer's and Dementia</i> , 2015, 11, P263.	0.8	4
42	Lymphatic Drainage Patterns in Oral Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 152, 673-677.	1.9	25
43	¹⁸ F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2015, 56, 222-228.	5.0	86
44	Regional Lymph Node Uptake of [¹⁸ F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 597-605.	0.8	19
45	Positron Emission Tomography for Subsequent Treatment Strategy in Oncology. <i>Journal of Clinical Oncology</i> , 2014, 32, 2811-2812.	1.6	2
46	Reply to J.-S. Ryu et al and A.T. Berman et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 1632-1633.	1.6	0
47	Impact of ¹⁸ F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1054-1061.	5.0	40
48	Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial. <i>Blood</i> , 2014, 124, 800-800.	1.4	30
49	Assessment of Progesterone Receptors in Breast Carcinoma by PET with ¹⁸ F-Fluoro-17β-[1-(1-furylmethylidene)Dioxo]-19-Norpregn-4-Ene-3,20-Dione. <i>Journal of Nuclear Medicine</i> , 2012, 53, 363-370.	5.0	71
50	Pelvic lymph node ¹⁸ F-fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. <i>Cancer</i> , 2010, 116, 1469-1475.	4.1	103
51	Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 774.	7.4	252
52	PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 509-517.	2.5	189
53	Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2289.	7.4	260
54	The standardized uptake value for ¹⁸ F-fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. <i>Cancer</i> , 2007, 110, 1738-1744.	4.1	271

#	ARTICLE	IF	CITATIONS
55	Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. <i>Cancer</i> , 2005, 104, 2484-2491.	4.1	168
56	Oncologic PET/CT: current status and controversies. <i>European Radiology, Supplement</i> , 2005, 15, d127-d132.	1.4	29
57	Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. <i>Journal of Nuclear Medicine</i> , 2003, 44, 700-7.	5.0	105
58	Lymph Node Staging by Positron Emission Tomography in Patients With Carcinoma of the Cervix. <i>Journal of Clinical Oncology</i> , 2001, 19, 3745-3749.	1.6	439
59	Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2797-2803.	1.6	377
60	FDG PET Evaluation of Mucinous Neoplasms. <i>American Journal of Roentgenology</i> , 2000, 174, 1005-1008.	2.2	300
61	Tc-99m sulfur colloid scintigraphy for detecting perigraft flow following endovascular aortic aneurysm repair: A feasibility study. <i>CardioVascular and Interventional Radiology</i> , 1999, 22, 447-451.	2.0	12
62	Surveillance of patients to detect recurrent thyroid carcinoma. , 1999, 85, 945-951.		43
63	Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. <i>Annals of Surgical Oncology</i> , 1997, 4, 613-620.	1.5	248
64	Clinical Pet Scanning: A "Short-lived" Orphan. <i>International Journal of Technology Assessment in Health Care</i> , 1992, 8, 610-622.	0.5	6
65	Ventilation imaging with Kr-81m. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1981, 6, 11-6.	2.1	6
66	Detection of accessory spleens with indium 111-labeled autologous platelets. <i>American Journal of Hematology</i> , 1980, 8, 81-86.	4.1	31
67	Indium-111: a New Radionuclide Label for Studying Human Platelet Kinetics. <i>British Journal of Haematology</i> , 1979, 42, 613-622.	2.5	172
68	The single palpable thyroid nodule. Evaluation by 99mTc-pertechnetate imaging. <i>Cancer</i> , 1976, 37, 258-265.	4.1	23
69	Effect of irradiation on tumor microvascular permeability to macromolecules. <i>Cancer</i> , 1972, 30, 639-642.	4.1	36
70	Effect of irradiation on tumor microvascular permeability to macromolecules. , 1972, 30, 639.		1
71	Pathophysiologic basis of soft tissue tumor scanning. <i>Journal of Surgical Oncology</i> , 1971, 3, 593-602.	1.7	9